首页> 外文期刊>Molecular cancer therapeutics >JAK-STAT and JAK-PI3K-mTORC1 Pathways Regulate Telomerase Transcriptionally and Posttranslationally in ATL Cells.
【24h】

JAK-STAT and JAK-PI3K-mTORC1 Pathways Regulate Telomerase Transcriptionally and Posttranslationally in ATL Cells.

机译:JAK-STAT和JAK-PI3K-mTORC1途径在ATL细胞中转录和翻译后调控端粒酶。

获取原文
获取原文并翻译 | 示例
           

摘要

Adult T-cell leukemia (ATL) is a heterogeneous tumor that is resistant to chemotherapy. Telomerase activity plays a critical role in tumorigenesis and is associated with the prognosis of ATL patients. Interleukin (IL)-2 commonly promotes tumor growth in chronic ATL cells. The signaling pathways involved in IL-2-regulated telomerase activation were studied in ATL cells derived from chronic ATL patients. IL-2 challenge enhanced tyrosine phosphorylation of Janus-activated kinase (JAK)1-3 and STAT5, and induced JAK1 and JAK2 to associate with STAT5 in IL-2-dependent ATL cells. Chromatin immunoprecipitation assays revealed that STAT5 directly bound to the human telomerase reverse transcriptase (hTERT) promoter. STAT5 short interfering RNA inhibited hTERT transcription in IL-2-stimulated ATL cells. Inhibitors of PI3K, HSP90, and mTOR reduced IL-2-induced hTERT mRNA, protein expression, and telomerase activity. AKT, HSP90, mTOR, S6 kinase, and hTERT immunoprecipitate from IL-2-stimulated cells contained telomerase activity, suggesting that hTERT directly interacts with, and is regulated by, these proteins. Binding of the p85 regulatory subunit of PI3K to JAK2 was enhanced in an IL-2-dependent manner, indicating that JAK2 propagates activation signals from the IL-2 receptor and links hTERT activation to both the STAT5 and PI3K pathways. Finally, IL-2-induced activation of telomerase and STAT5 was observed in primary leukemic cells. These results indicate that IL-2 stimulation induces hTERT activation through the JAK/STAT pathway and the JAK/PI3K/AKT/HSP90/mTORC1 pathway in IL-2-responsive ATL cells. These signaling proteins represent novel and promising molecular therapeutic targets for IL-2-dependent ATL. Mol Cancer Ther; 11(5); 1112-21. ?2012 AACR.
机译:成人T细胞白血病(ATL)是一种对化疗耐药的异质性肿瘤。端粒酶活性在肿瘤发生中起关键作用,并与ATL患者的预后有关。白介素(IL)-2通常促进慢性ATL细胞中的肿瘤生长。在源自慢性ATL患者的ATL细胞中研究了涉及IL-2调节的端粒酶激活的信号通路。 IL-2攻击增强了Janus激活激酶(JAK)1-3和STAT5的酪氨酸磷酸化,并诱导依赖IL-2的ATL细胞中JAK1和JAK2与STAT5结合。染色质免疫沉淀试验表明,STAT5直接与人类端粒酶逆转录酶(hTERT)启动子结合。 STAT5短干扰RNA抑制IL-2刺激的ATL细胞中的hTERT转录。 PI3K,HSP90和mTOR抑制剂可降低IL-2诱导的hTERT mRNA,蛋白表达和端粒酶活性。来自IL-2刺激的细胞的AKT,HSP90,mTOR,S6激酶和hTERT免疫沉淀物含有端粒酶活性,表明hTERT与这些蛋白质直接相互作用并受其调节。 PI3K的p85调节亚基与JAK2的结合以依赖IL-2的方式增强,这表明JAK2传播来自IL-2受体的激活信号并将hTERT激活与STAT5和PI3K途径相关。最后,在原代白血病细胞中观察到IL-2诱导的端粒酶和STAT5的激活。这些结果表明,IL-2刺激通过IL-2反应性ATL细胞中的JAK / STAT途径和JAK / PI3K / AKT / HSP90 / mTORC1途径诱导hTERT激活。这些信号蛋白代表依赖IL-2的ATL的新型和有希望的分子治疗靶标。分子癌疗法; 11(5); 1112-21。 2012年AACR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号